NCT00532506

Brief Summary

The purpose of this study is to evaluate the clinical efficacy and safety of SK-0403 in patients with Type2 Diabetes Mellitus

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 19, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 20, 2007

Completed
Last Updated

October 10, 2008

Status Verified

October 1, 2008

First QC Date

September 19, 2007

Last Update Submit

October 8, 2008

Conditions

Interventions

Eligibility Criteria

Age20 Years - 74 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Treatment-naive subjects diagnosed with type 2 diabetes mellitus
  • Stable diet program for at least 8 weeks
  • Criteria for HbA1c are met

You may not qualify if:

  • Type 1 diabetes
  • Patients treated with other antidiabetic drugs or Insulin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Unknown Facility

Fukuoka, Japan

Location

Unknown Facility

Gifu, Japan

Location

Unknown Facility

Gunma, Japan

Location

Unknown Facility

Hokkaido, Japan

Location

Unknown Facility

Ibaraki, Japan

Location

Unknown Facility

Kanagawa, Japan

Location

Unknown Facility

Kumamoto, Japan

Location

Unknown Facility

Okinawa, Japan

Location

Unknown Facility

Ōita, Japan

Location

Unknown Facility

Tokyo, Japan

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Ryuzo Kawamori, M.D.

    Juntendo University School of Medicine, Dept. of Endocrinology and Metabolism

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 19, 2007

First Posted

September 20, 2007

Last Updated

October 10, 2008

Record last verified: 2008-10

Locations